CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended June 30, 2024 and provided an overview of its recent operational highlights.
“We have continued to advance TRV045 in the second quarter,” said Carrie Bourdow, President and CEO of Trevena. “We believe the most recent data further supports TRV045’s therapeutic potential and differentiated MOA and its potential to address the need for novel, non-opioid therapies for treating neuropathic pain and epilepsy.”
Second Quarter 2024 and Recent Corporate Highlights
Financial Results and Other Updates for First Quarter 2024
For the second quarter of 2024, the Company reported a net loss attributable to common stockholders of $4.9 million, or $0.23 per share, compared to $8.0 million, or $0.69 per share in the second quarter of 2023. Cash and cash equivalents were $16.4 million as of June 30, 2024, not including the $2 million in gross proceeds received from R-Bridge in July 2024.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.
For more information, please visit www.Trevena.com
About TRV045
TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy.
S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability.
Trevena’s discovery efforts have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above pharmacologically active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the FDA. Subjects in both studies referenced in this press release were enrolled outside of the United States, and the studies were not conducted under the Investigational New Drug Application for TRV045.
About OLINVYK® (oliceridine) injection
OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE
OF OLINVYK
Addiction, Abuse, and Misuse
Because the use of OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of OLINVYK are essential.
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of OLINVYK and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
Neonatal Opioid Withdrawal Syndrome
If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.
INDICATIONS AND USAGE
OLINVYK is an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Limitations of Use
Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, reserve OLINVYK for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
The cumulative total daily dose should not exceed 27 mg.
CONTRAINDICATIONS
OLINVYK is contraindicated in patients with:
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
Adverse reactions are described in greater detail in the Prescribing Information.
The most common (incidence ≥10%) adverse reactions in Phase 3 controlled clinical trials were nausea, vomiting, dizziness, headache, constipation, pruritus, and hypoxia.
MEDICAL INFORMATION
For medical inquiries or to report an adverse event, other safety-related information or product complaints for a company product, please contact the Trevena Medical Information Contact Center at 1-844-465-4686 or email This email address is being protected from spambots. You need JavaScript enabled to view it..
You are encouraged to report suspected adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
PLEASE see www.OLINVYK.com for full prescribing information including BOXED warning and important safety information
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the expectations surrounding the continued advancement of the Company’s product pipeline; the potential safety and efficacy of the Company’s product candidates and their regulatory and clinical development; the Company’s intention to pursue strategic alternatives for OLINVYK and the ability of any such strategic alternative to provide shareholder value; the expected financial and operational impacts of the Company’s decision to reduce commercial support for OLINVYK; the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of discussions with FDA; available funding; uncertainties related to continued listing on NASDAQ; uncertainties related to the Company’s intellectual property; uncertainties related to other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
For more information, please contact:
Company Contact:
Bob Yoder
SVP, Chief Business Officer & Head of Commercial Operations
Trevena, Inc.
(610) 354-8840
TREVENA, INC. | ||||||||||||||||
Condensed Statements of Operations | ||||||||||||||||
(Unaudited, in thousands except share and per share data) | ||||||||||||||||
Three Months Ended Jun 30, | Six Months Ended Jun 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Product revenue | $ | 14 | $ | 21 | $ | 34 | $ | 27 | ||||||||
License revenue | 311 | 3,000 | 311 | 3,000 | ||||||||||||
Total revenue | 325 | 3,021 | 345 | 3,027 | ||||||||||||
Operating expenses: | ||||||||||||||||
Cost of goods sold | 103 | 88 | 191 | 214 | ||||||||||||
Selling, general and administrative | 3,598 | 5,138 | 9,443 | 11,227 | ||||||||||||
Research and development | 3,127 | 3,991 | 7,092 | 7,900 | ||||||||||||
Total operating expenses | 6,828 | 9,217 | 16,726 | 19,341 | ||||||||||||
Loss from operations | (6,503 | ) | (6,196 | ) | (16,381 | ) | (16,314 | ) | ||||||||
Other income (expense) | 1,612 | (1,816 | ) | 3,812 | 483 | |||||||||||
Net loss | $ | (4,891 | ) | $ | (8,012 | ) | $ | (12,569 | ) | $ | (15,831 | ) | ||||
Per share information: | ||||||||||||||||
Net loss per share of common stock, basic and diluted | ($0.23 | ) | ($0.69 | ) | ($0.59 | ) | ($1.49 | ) | ||||||||
Weighted average shares outstanding, basic and diluted | 21,318,073 | 11,580,128 | 21,310,772 | 10,592,586 | ||||||||||||
TREVENA, INC. | ||||||||
Condensed Balance Sheets | ||||||||
(Unaudited, in thousands) | ||||||||
June 30, 2024 | December 31, 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 16,367 | $ | 32,975 | ||||
Prepaid expenses and other current assets | 1,664 | 2,230 | ||||||
Total current assets | 18,031 | 35,205 | ||||||
Restricted cash | 540 | 540 | ||||||
Property and equipment, net | 1,018 | 1,195 | ||||||
Right-of-use lease assets | 3,354 | 3,665 | ||||||
Total assets | $ | 22,943 | $ | 40,605 | ||||
Liabilities and stockholders’ (deficit) equity | ||||||||
Current liabilities: | ||||||||
Accounts payable, net | $ | 1,132 | $ | 2,303 | ||||
Accrued expenses and other current liabilities | 3,002 | 4,239 | ||||||
Current portion of lease liabilities | 1,072 | 1,012 | ||||||
Total current liabilities | 5,206 | 7,554 | ||||||
Loans payable, net | 31,527 | 30,809 | ||||||
Leases, net of current portion | 3,875 | 4,424 | ||||||
Warrant liability | 1,292 | 5,475 | ||||||
Total liabilities | 41,900 | 48,262 | ||||||
Common stock | 21 | 17 | ||||||
Additional paid-in capital | 581,652 | 580,387 | ||||||
Accumulated deficit | (600,630 | ) | (588,061 | ) | ||||
Total stockholders’ (deficit) equity | (18,957 | ) | (7,657 | ) | ||||
Total liabilities and stockholders’ (deficit) equity | $ | 22,943 | $ | 40,605 | ||||
Last Trade: | US$1.70 |
Daily Change: | -0.28 -14.14 |
Daily Volume: | 1,722 |
Market Cap: | US$1.450M |
December 28, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB